Oligosaccharides as anti-angiogenic agents

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Tumor angiogenesis is a validated therapeutic target, with both intracellular and extracellular strategies showing clinical promise.
• Inhibiting tumor angiogenesis improves survival rates in cancer patients.

Purpose of the Study:

• To compare and contrast oligosaccharide therapies with other anti-angiogenic compounds regarding their benefits and toxicity.
• To evaluate the potential of oligosaccharides as a novel therapeutic strategy in cancer treatment.

Main Methods:

• Systematic literature review, including analysis of conference presentations.
• Comparative analysis of different anti-angiogenic drug classes.

Main Results:

• Receptor tyrosine kinase inhibitors (RTKIs) are orally available but exhibit broad activity and associated toxicities.
• Antibodies, while effective, are administered parenterally and have distinct toxicity profiles.
• Oligosaccharides targeting heparan sulfate (HS) are in clinical development, offering potential for multi-target inhibition, improved safety, and subcutaneous administration.

Conclusions:

• Saccharides represent a novel therapeutic approach targeting angiogenic molecules inaccessible to current drug development programs.
• Oligosaccharides offer a promising alternative with potential advantages in specificity, safety, and administration route.